Back to Agenda
Session 7 Track D: Biosimilars: What the Communicator Should Know About This Growing Field
Session Chair(s)
Lawrence Liberti, PhD, RAC
Director, D.K. Kim International Center for Regulatory Science
The Kim Center/ USC DRQS, United States
This session is aimed at regulatory writers and publications/medical communications writers who have an interest in preparing communications describing biosimilars products. The objective is to help participants recognize differences in communicating about the chemistry, pharmacology and other characteristics of biosimilars distinct from small molecules and generics.
Learning Objective : At the conclusion of this session, participants should be able to:- Recognize the differences between a biosimilars, small molecule, biologic and generic product
- Describe the special approaches required to communicate regulatory and clinical concepts regarding biosimilars
- Discuss the role of biosimilars in global health care
Speaker(s)
Biosimilars 101: A Primer
Matthew Frankel, MD, MBA
Sandoz Inc., United States
Executive Director, Medical Affairs Biopharmaceuticals North America
Communicating About Biosimilars: Building on Your Experience - Exploring a New Path
Eileen Girten, MS
Pfizer Inc, United States
Director, Medical Writing
Why Biosimilars Matter: Their Global Role in Modern Therapy
Lawrence Liberti, PhD, RAC
The Kim Center/ USC DRQS, United States
Director, D.K. Kim International Center for Regulatory Science
Have an account?